Regorafenib Improves OS in Asian Patients with mCRC after Previous Failure with Standard Therapy

The oral multikinase inhibitor regorafenib targets multiple pathways involved in tumor development and progression. In the CORRECT study [Grothey A et al. Lancet. 2013], treatment with regorafenib improved overall survival (OS) in patients with metastatic colorectal cancer (mCRC) disease progression after standard therapies (HR, 0.77; 95% CI, 0.64 to 0.94; 1-sided p?=?.0052). This article presents the results from the Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy study [CONCUR; NCT01584830], a trial examining the efficacy and safety of regorafenib in a larger group of Asian patients with mCRC.